Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats-Reference-Cited by-同舟云学术

Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats

Published:2007 Issue:4 Volume:46 Page:1208-1217
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Fernandez Mercedes,Mejias Marc,Garcia-Pras Ester,Mendez Raul,Garcia-Pagan Juan Carlos,Bosch Jaime

Publisher

Wiley

Subject

Hepatology

Reference28 articles.

1. PATHOPHYSIOLOGY OF PORTAL HYPERTENSION

2. . The splanchnic circulation in cirrhosis. In: , , , eds. Ascites and Renal Dysfunction in Liver Disease. Pathogenesis, Diagnosis, and Treatment. Malden, MA: Blackwell Publishing; 2005: 125–136.

3. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice

4. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats

5. Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats

Cited by 160 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of vascular intervention plus lenvatinib versus vascular intervention alone for hepatocellular carcinoma patients with portal vein tumor thrombus: a retrospective comparative study;Frontiers in Oncology;2024-07-05

2. Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives;Cancers;2024-03-31

3. Curcumol Attenuates Portal Hypertension and Collateral Shunting Via Inhibition of Extrahepatic Angiogenesis in Cirrhotic Rats;Biochemical Genetics;2024-03-04

4. The challenges and potential of microRNA-based therapy for patients with liver failure syndromes and hepatocellular carcinoma;Expert Opinion on Therapeutic Targets;2024-03-03

5. Activation of cGAS-STING signaling pathway promotes liver fibrosis and hepatic sinusoidal microthrombosis;International Immunopharmacology;2023-12